Mirum Pharmaceuticals (MIRM) Amortization of Deferred Charges (2021 - 2026)

Mirum Pharmaceuticals' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $454000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 4.85% year-over-year to $454000.0 in Q1 2026; TTM through Mar 2026 was $1.8 million, a 4.76% increase from a year earlier, with the FY2025 full-year figure at $1.7 million, up 4.7% from the prior year.
• Amortization of Deferred Charges grew to $454000.0 in Q1 2026 per MIRM's latest filing, from $436000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $454000.0 in Q1 2026 and bottomed at -$101000.0 in Q2 2022.
• The 5-year median for Amortization of Deferred Charges is $415000.0 (2024), against an average of $355071.4.
• Across the five-year window, Amortization of Deferred Charges plunged 205.21% in 2022 and soared 403.96% in 2023, its largest moves.
• Year by year, Amortization of Deferred Charges stood at -$101000.0 in 2022, then surged by 495.05% to $399000.0 in 2023, then rose by 4.26% to $416000.0 in 2024, then rose by 4.81% to $436000.0 in 2025, then gained by 4.13% to $454000.0 in 2026.
• Per Business Quant, the three latest MIRM Amortization of Deferred Charges figures stand at $454000.0 (Q1 2026), $436000.0 (Q4 2025), and $443000.0 (Q3 2025).